Dermatomyositis Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-03-25　·　152 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 637.7 Mn
2033 年預估規模: USD 931.6 Mn
年複合成長率 CAGR: 5.5%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-03-25頁數 152報告編號 CMI5250

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Dermatomyositis Market, By Type (Adult Dermatomyositis, Dermatomyositis Sine Myositis, and Juvenile (Childhood) Dermatomyositis (JDMS)), By Treatment Type (Anti-inflammatory Medication, Immunosuppressive Drugs, Immunoglobulin, Others (Plasma Exchange, Monoclonal antibody among others)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)

報告摘要

Dermatomyositis is a rare condition that causes muscle inflammation. It presents with symmetric proximal muscle weakness, skin rash, and extra macular manifestations such as esophageal dysfunction and interstitial lung disease. Dermatomyositis is strongly associated with malignancy, especially in adults. Dermatomyositis is a systemic disorder that most frequently affects the skin and muscles but may also affect the joints, the esophagus, the lungs, and less commonly, the heart. Dermatomyositis presents with characteristic skin findings and symmetric proximal skeletal muscle weakness. It can also affect other organ systems such as the pulmonary, cardiovascular, and gastrointestinal systems. Various factors cause dermatomyositis such as genetic factors, immunologic factors, and environmental factors such as infections, drugs, and radiation. Furthermore, there are three types of dermatomyositis namely, Adult Dermatomyositis, Dermatomyositis Sine Myositis, and Juvenile (Childhood) Dermatomyositis (JDMS). Dermatomyositis Sine Myositis is a term used to describe patients who are present with the dermatological features of dermatomyositis but an absence of associated muscle findings. Juvenile (childhood) dermatomyositis (JDMS) is an early onset form of dermatomyositis (DM), a systemic, autoimmune inflammatory muscle disorder with vasculopathy, characterized by proximal and symmetrical muscle weakness, evocative skin lesions, and systemic manifestations. Market Dynamics Market players are involved in the development of novel treatment for dermatomyositis which is expected to propel the market growth over the forecast period. For instance, in May 2022, Kezar Life Sciences, Inc., a clinical-stage biotechnology company, announced result from the PRESIDIO Phase 2 clinical trial of zetomipzomib (KZR-616) in patients with dermatomyositis (DM) and polymyositis (PM). The results of the PRESIDIO trial showed that most DM and PM patients saw clinically meaningful improvements in total improvement score (TIS). Key features of the study • This report provides an in-depth analysis of the global dermatomyositis market, market size (USD Mn), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global dermatomyositis market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies • Key companies covered as a part of this study include AstraZeneca Plc., Bristol-Myers Squibb Company, Octapharma AG, Corbus Pharmaceuticals Holdings, Inc., CSL Limited, Ermium Therapeutics, Kezar Life Sciences Inc., Mallinckrodt Plc., Néovacs, Horizon Therapeutics plc., and Pfizer Inc. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global dermatomyositis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatomyositis market Dermatomyositis Market Segmentation • By Type (Revenue, USD Mn, 2020 - 2033) o Adult Dermatomyositis o Dermatomyositis Sine Myositis o Juvenile (Childhood) Dermatomyositis (JDMS) • By Treatment Type Insights (Revenue, USD Mn, 2020 - 2033) o Anti-inflammatory Medication o Immunosuppressive Drugs o Immunoglobulin o Others (Plasma Exchange, Monoclonal antibody among others) • By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • By Region Insights (Revenue, USD Mn, 2020 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East & Africa  GCC Countries  Israel  Rest of Middle East & Africa • Key Players o AstraZeneca Plc. o Bristol-Myers Squibb Company o Octapharma AG o Corbus Pharmaceuticals Holdings, Inc. o CSL Limited o Ermium Therapeutics o Kezar Life Sciences Inc. o Mallinckrodt Plc. o Néovacs, Horizon Therapeutics plc. o Pfizer Inc.

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snapshot, By Type  Market Snapshot, By Treatment Type  Market Snapshot, By Distribution Channel  Market Snapshot, By Region  Market Opportunity Map 3. Global Dermatomyositis Market Insights o Drivers o Restraints o Opportunity o Impact Analysis o Pipeline Analysis o PEST Analysis o Porter’s Five Forces Analysis o Key Developments o Regulatory Scenario o Reimbursement Scenario o Merger & Acquisition Scenario o Brand Mapping 4. Global Dermatomyositis Market, By Type, 2026 – 2033 (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2026 – 2033  Segment Trends o Adult Dermatomyositis  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o Dermatomyositis Sine Myositis  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o Juvenile (Childhood) Dermatomyositis (JDMS)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) 5. Global Dermatomyositis Market, By Treatment Type, 2026 – 2033 (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2026 – 2033  Segment Trends o Anti-inflammatory Medication  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o Immunosuppressive Drugs  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o Immunoglobulin  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o Others (Plasma Exchange, Monoclonal antibody among others)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) 6. Global Dermatomyositis Market, By Distribution Channel, 2026 – 2033 (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2026 – 2033  Segment Trends o Hospital Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) o Retail Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn o Online Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033 (USD Mn) 7. Global Dermatomyositis Market, By Region, 2026 – 2033 (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2026 – 2033  Region at Trends o North America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (USD Mn)  Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020–2033, (USD Mn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (USD Mn)  Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020–2033, (USD Mn) o Brazil o Mexico o Argentina o Rest of Latin America o Europe  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (USD Mn)  Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2020–2033, (USD Mn) o Germany o U.K. o France o Italy o Spain o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (USD Mn)  Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020–2033, (USD Mn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (USD Mn)  Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020–2033, (USD Mn) o GCC o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 – 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (USD Mn)  Market Size and Forecast by Value, and Y-o-Y Growth, By Country/Region, 2020–2033, (USD Mn) o South Africa o Central Africa o North Africa 8. Company Profiles o AstraZeneca Plc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Bristol-Myers Squibb Company  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Octapharma AG  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Corbus Pharmaceuticals Holdings, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o CSL Limited  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Ermium Therapeutics  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Kezar Life Sciences Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Mallinckrodt Plc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Néovacs  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Horizon Therapeutics plc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Pfizer Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies 9. Section o Research Methodology o About us

提及公司

AstraZeneca Plc.Bristol-Myers Squibb CompanyOctapharma AGCorbus Pharmaceuticals Holdings, Inc.CSL LimitedErmium TherapeuticsKezar Life Sciences Inc.Mallinckrodt Plc.Néovacs, Horizon Therapeutics plc.Pfizer Inc.

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們